CY2245B1 - Treatment of incontinence with venlafaxine or an aryloxy propanamine compound - Google Patents

Treatment of incontinence with venlafaxine or an aryloxy propanamine compound

Info

Publication number: CY2245B1
Authority: CY; Cyprus
Prior art keywords: venlafaxine; aryloxy; incontinence; treatment; compound
Prior art date: 1993-11-24

Application number

CY0100037A

Other languages

English (en)

Inventor

Karl Bruce Thor

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-24

Filing date

2001-11-14

Publication date

2003-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2245(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-11-14 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-07-04 Publication of CY2245B1 publication Critical patent/CY2245B1/xx

Links

-1 aryloxy propanamine compound Chemical class 0.000 title abstract 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title abstract 2
229960004688 venlafaxine Drugs 0.000 title abstract 2
206010021639 Incontinence Diseases 0.000 title 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Furan Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
External Artificial Organs (AREA)

CY0100037A 1993-11-24 2001-11-14 Treatment of incontinence with venlafaxine or an aryloxy propanamine compound CY2245B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15812193A	1993-11-24	1993-11-24

Publications (1)

Publication Number	Publication Date
CY2245B1 true CY2245B1 (en)	2003-07-04

Family

ID=22566762

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY0100037A CY2245B1 (en)	1993-11-24	2001-11-14	Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
CY2005002C CY2005002I2 (el)	1993-11-24	2005-02-10	Χρηση της βενλαφαξινης ή μιας ενωσης αρυλοξυ προπαναμινης για την παρασκευη ενος φαρμακου για την αγωγη της ουρικης ακρατειας

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY2005002C CY2005002I2 (el)	1993-11-24	2005-02-10	Χρηση της βενλαφαξινης ή μιας ενωσης αρυλοξυ προπαναμινης για την παρασκευη ενος φαρμακου για την αγωγη της ουρικης ακρατειας

Country Status (27)

Country	Link
US (1)	US5744474A (fr)
EP (1)	EP0654264B1 (fr)
JP (1)	JP3681009B2 (fr)
KR (1)	KR100347277B1 (fr)
CN (1)	CN1099284C (fr)
AT (1)	ATE201594T1 (fr)
AU (1)	AU679269B2 (fr)
CA (1)	CA2136120C (fr)
CY (2)	CY2245B1 (fr)
CZ (1)	CZ289069B6 (fr)
DE (2)	DE122005000005I2 (fr)
DK (1)	DK0654264T3 (fr)
ES (1)	ES2157958T3 (fr)
GE (1)	GEP20064000B (fr)
GR (1)	GR3036446T3 (fr)
HU (1)	HU218920B (fr)
IL (1)	IL111705A (fr)
LU (1)	LU91140I2 (fr)
NL (1)	NL300174I2 (fr)
NO (2)	NO313535B1 (fr)
PH (1)	PH30741A (fr)
PT (1)	PT654264E (fr)
RU (1)	RU2152786C2 (fr)
SI (1)	SI0654264T1 (fr)
TW (1)	TW344661B (fr)
UA (1)	UA32429C2 (fr)
ZA (1)	ZA949190B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506270A (en) *	1995-01-30	1996-04-09	American Home Products Corporation	Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
EA001325B1 (ru) *	1996-03-11	2001-02-26	Эли Лилли Энд Компани	Способы лечения и профилактики интерстициального цистита
US6274171B1 (en)	1996-03-25	2001-08-14	American Home Products Corporation	Extended release formulation of venlafaxine hydrochloride
EP1331003B1 (fr) *	1996-03-25	2015-08-26	Wyeth LLC	Composition de venlafaxine à libération prolongée
PE57198A1 (es) *	1996-03-25	1998-10-10	American Home Prod	Formula de liberacion prolongada
US6150396A (en) *	1997-03-07	2000-11-21	Eli Lilly And Company	Methods of treating or preventing interstitial cystitis
US6579899B1 (en)	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress
JP2002520353A (ja) *	1998-07-16	2002-07-09	マサチューセッツインスティテュートオブテクノロジー	ストレスの処置のための組成物
SK287111B6 (sk) *	1998-08-27	2009-12-07	Pharmacia & Upjohn Ab	Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
US6046242A (en) *	1998-11-27	2000-04-04	Basf Aktiengesellschaft	Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) *	1998-12-01	2002-01-29	Sepracor, Inc.	Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) *	1998-12-01	2001-03-06	Sepracor, Inc.	Derivatives of (+)-venlafaxine and methods of preparing and using the same
DE60039132D1 (de) *	1999-04-06	2008-07-17	Sepracor Inc	O-Desmethylvenlafaxin-Succinat
US6465458B1 (en) *	1999-07-01	2002-10-15	Pharmacia & Upjohn Company	Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
US7291646B2 (en)	1999-11-24	2007-11-06	Wyeth	Ethers of O-desmethyl venlafaxine
US6572890B2 (en) *	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de)	2000-06-02	2002-07-11	Basf Coatings Ag	Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de)	2000-11-30	2002-06-13	Gruenenthal Gmbh	Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
EP1864967A1 (fr) *	2001-02-12	2007-12-12	Wyeth	Procédé de fabrication d'O-desméthyl-venlafaxine
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
UA77234C2 (en) *	2001-12-05	2006-11-15	Wyeth Corp	Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
CN1630631A (zh) *	2001-12-05	2005-06-22	惠氏公司	新的文拉法星盐酸盐多晶型物及其制备方法
GB0202265D0 (en) *	2002-01-31	2002-03-20	Arachnova Therapeutics Ltd	New therapeutic use
US6696496B2 (en) *	2002-03-28	2004-02-24	Synthon Bv	Low water-soluble venlafaxine salts
US20030232805A1 (en) *	2002-04-24	2003-12-18	Cypress Bioscience, Inc.	Prevention and treatment of functional somatic disorders, including stress-related disorders
DE10224107A1 (de) *	2002-05-29	2003-12-11	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
WO2004019892A2 (fr) *	2002-08-30	2004-03-11	Watson Pharmaceuticals, Inc.	Systeme ameliore de delivrance de medicaments pour le traitement de l'incontinence urinaire
GB0221438D0 (en) *	2002-09-16	2002-10-23	Avecia Ltd	Processes and compounds
EP1424079A1 (fr) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
US20070077301A1 (en) *	2002-12-23	2007-04-05	Meyer Glenn A	Venlafaxine osmotic device formulation
EP1539181B1 (fr) *	2003-04-04	2007-06-27	Dynogen Pharmaceuticals Inc.	Methode de traitement de troubles des voies urinaires inferieures
BRPI0510453A (pt) *	2004-04-30	2007-10-30	Warner Lambert Co	composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
EP2248524A3 (fr)	2004-08-25	2011-03-09	Takeda Pharmaceutical Company Limited	Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
WO2006071868A2 (fr) *	2004-12-23	2006-07-06	Teva Pharmaceutical Industries Ltd.	Processus de preparation de sels de duloxetine repondant aux normes pharmaceutiques et d'intermediaires de ceux-ci
CA2599478A1 (fr) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Procede de purification de la duloxetine hydrochloride
EP1838692A2 (fr)	2005-09-22	2007-10-03	Teva Pharmaceutical Industries Ltd	Dnt-maleate, procedes de preparation de dernier
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
HUE027865T2 (en)	2005-12-01	2016-11-28	Auspex Pharmaceuticals Inc	Substituted phenyl ethylamines with serotonergic and / or norepinephrine activity
US7759500B2 (en)	2005-12-05	2010-07-20	Teva Pharmaceutical Industries Ltd.	2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
US7612210B2 (en)	2005-12-05	2009-11-03	Wyeth	Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
EP1826204A1 (fr)	2006-02-28	2007-08-29	Laboratorios Del Dr. Esteve, S.A.	Procédé pour la préparation des précurseurs de duloxetine
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008140859A1 (fr)	2007-03-15	2008-11-20	Auspex Pharmaceuticals, Inc.	Phénéthylamines substituées à action sérotoninergique et/ou norépinéphrinergique
WO2020014336A1 (fr)	2018-07-11	2020-01-16	Dignify Therapeutics, Llc	Procédé de traitement d'un dysfonctionnement de vide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4018895A (en) *	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
GR75395B (fr) *	1980-11-14	1984-07-13	Lilly Co Eli
IE56324B1 (en) *	1982-12-13	1991-06-19	American Home Prod	Phenethylamine derivatives and intermediates therefor
US4761501A (en) *	1983-10-26	1988-08-02	American Home Products Corporation	Substituted phenylacetamides
US4956388A (en) *	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
KR880007433A (ko) *	1986-12-22	1988-08-27	메리 앤 터커	3-아릴옥시-3-치환된 프로판아민
PT87163B (pt) *	1987-04-09	1992-07-31	Lilly Co Eli	Processo para a preparacao de 1-fenil-3-naftaleniloxi-propanaminas
US5236956A (en) *	1988-11-04	1993-08-17	Kabi Pharmacia Aktiebolag	Compounds for the treatment of urinary incontinence
SE8804003D0 (sv) *	1988-11-04	1988-11-04	Pharmacia Ab	Compounds for the treatment of urinary incontinence
US5250571A (en) *	1988-11-14	1993-10-05	Eli Lilly And Company	(S)-norfluoxetine in method of inhibiting serotonin uptake
DE3912232A1 (de) *	1989-04-11	1989-11-30	Klosa Josef	Mittel gegen harninkontinenz
PH30083A (en) *	1991-02-25	1996-12-27	Lilly Co Eli	Treatment of lower urinary tract disorders
US5281624A (en) *	1991-09-27	1994-01-25	Eli Lilly And Company	N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) *	1991-09-27	1995-11-27	Lilly Co Eli	N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
EP0617620B1 (fr) *	1991-12-21	1998-09-09	Smithkline Beecham Plc	Utilisation d'antagonistes au recepteur 5-ht 4 pour fabriquer un medicament pour le traitement de l'incontinence urinaire
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-05-12 TW TW083104298A patent/TW344661B/zh not_active IP Right Cessation
- 1994-11-18 CA CA002136120A patent/CA2136120C/fr not_active Expired - Lifetime
- 1994-11-18 ZA ZA949190A patent/ZA949190B/xx unknown
- 1994-11-21 UA UA94119056A patent/UA32429C2/uk unknown
- 1994-11-21 IL IL11170594A patent/IL111705A/en not_active IP Right Cessation
- 1994-11-21 PH PH49414A patent/PH30741A/en unknown
- 1994-11-21 NO NO19944456A patent/NO313535B1/no not_active IP Right Cessation
- 1994-11-22 AU AU78968/94A patent/AU679269B2/en not_active Expired
- 1994-11-22 KR KR1019940030696A patent/KR100347277B1/ko not_active Expired - Lifetime
- 1994-11-22 SI SI9430379T patent/SI0654264T1/xx unknown
- 1994-11-22 ES ES94308604T patent/ES2157958T3/es not_active Expired - Lifetime
- 1994-11-22 DK DK94308604T patent/DK0654264T3/da active
- 1994-11-22 PT PT94308604T patent/PT654264E/pt unknown
- 1994-11-22 DE DE1994627337 patent/DE122005000005I2/de active Active
- 1994-11-22 AT AT94308604T patent/ATE201594T1/de active
- 1994-11-22 EP EP94308604A patent/EP0654264B1/fr not_active Expired - Lifetime
- 1994-11-22 DE DE69427337T patent/DE69427337T2/de not_active Expired - Lifetime
- 1994-11-22 JP JP28811994A patent/JP3681009B2/ja not_active Expired - Lifetime
- 1994-11-23 RU RU94041950/14A patent/RU2152786C2/ru active
- 1994-11-23 CN CN94118993A patent/CN1099284C/zh not_active Expired - Lifetime
- 1994-11-23 HU HU9403369A patent/HU218920B/hu unknown
- 1994-11-23 CZ CZ19942893A patent/CZ289069B6/cs not_active IP Right Cessation
1995
- 1995-04-20 US US08/425,703 patent/US5744474A/en not_active Expired - Lifetime
2001
- 2001-08-27 GR GR20010401296T patent/GR3036446T3/el unknown
- 2001-11-14 CY CY0100037A patent/CY2245B1/xx unknown
2005
- 2005-02-04 LU LU91140C patent/LU91140I2/fr unknown
- 2005-02-09 NO NO2005004C patent/NO2005004I1/no unknown
- 2005-02-10 NL NL300174C patent/NL300174I2/nl unknown
- 2005-02-10 CY CY2005002C patent/CY2005002I2/el unknown
2006
- 2006-05-23 GE GEAP20069411A patent/GEP20064000B/en unknown

Also Published As

Publication number	Publication date
RU94041950A (ru)	1996-09-20
RU2152786C2 (ru)	2000-07-20
NO944456L (no)	1995-05-26
JPH07188003A (ja)	1995-07-25
ATE201594T1 (de)	2001-06-15
NL300174I2 (nl)	2005-05-02
DE122005000005I1 (de)	2005-05-12
NO313535B1 (no)	2002-10-21
NO944456D0 (no)	1994-11-21
DK0654264T3 (da)	2001-07-30
CN1107699A (zh)	1995-09-06
CA2136120A1 (fr)	1995-05-25
NL300174I1 (nl)	2005-04-01
PT654264E (pt)	2001-09-28
CY2005002I1 (el)	2010-07-28
CZ289069B6 (cs)	2001-10-17
JP3681009B2 (ja)	2005-08-10
ES2157958T3 (es)	2001-09-01
KR950013511A (ko)	1995-06-15
IL111705A (en)	2001-01-11
ZA949190B (en)	1996-05-20
UA32429C2 (uk)	2000-12-15
GEP20064000B (en)	2006-12-11
CZ289394A3 (en)	1995-07-12
DE69427337T2 (de)	2001-10-31
US5744474A (en)	1998-04-28
LU91140I2 (fr)	2005-04-04
CA2136120C (fr)	2008-01-29
EP0654264B1 (fr)	2001-05-30
HK1013799A1 (en)	1999-09-10
CY2005002I2 (el)	2010-07-28
AU7896894A (en)	1995-06-01
HU218920B (hu)	2000-12-28
TW344661B (en)	1998-11-11
DE122005000005I2 (de)	2006-06-08
HU9403369D0 (en)	1995-02-28
GR3036446T3 (en)	2001-11-30
DE69427337D1 (de)	2001-07-05
AU679269B2 (en)	1997-06-26
HUT72317A (en)	1996-04-29
NO2005004I1 (no)	2005-02-10
KR100347277B1 (ko)	2003-03-06
SI0654264T1 (en)	2001-10-31
EP0654264A1 (fr)	1995-05-24
PH30741A (en)	1997-10-17
IL111705A0 (en)	1995-01-24
CN1099284C (zh)	2003-01-22

Publication	Publication Date	Title
CY2245B1 (en)	2003-07-04	Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
TW249226B (fr)	1995-06-11
AU3107993A (en)	1993-07-15	Method of treating hyperproliferative vascular disease
IL102414A0 (en)	1993-01-14	Method of treating ocular inflammation
GR3024746T3 (en)	1997-12-31	Rs-thioctic acid with a new morphology
GR3018226T3 (en)	1996-02-29	Sulfonanilide derivative and medicine.
NZ247406A (en)	1999-05-28	Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
AU609637B2 (en)	1991-05-02	Process for the treatment of effluents containing cyanide and/or other oxidizable substances
GR3025394T3 (en)	1998-02-27	Process for the purifying of waters for human consumption.
AU7877894A (en)	1995-04-10	Treatment of hiv infection with humic acid
ZA941729B (en)	1994-10-13	Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).
AU7375994A (en)	1995-02-28	Treatment of cyanides in effluents with caro's acid
TW288066B (fr)	1996-10-11
AU7719491A (en)	1991-11-28	Therapeutic compound
CA2561293A1 (fr)	1995-05-25	Traitement de l'incontinence
AU1282592A (en)	1993-05-20	Method for treatment for neuro-muscular incontinence
AU5051090A (en)	1990-08-30	A method of treatment or prevention of post-PTCA restenosis by post-PTCA restenosis inhibitor
PL288858A1 (en)	1992-08-10	Active sludge chamber of a biological treatment plant